Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 58, Issue 3, 2006, Pages 285-291

  Yamamoto, Nobuyuki ^a,b   Nishimura, Yasumasa ^a   Nakagawa, Kazuhiko ^a   Matsui, Kaoru ^c   Fukuoka, Masahiro ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHIZUOKA CANCER CENTER   (Japan)

^c OSAKA GENERAL MEDICAL CENTER   (Japan)

Author keywords

AAG; Chemoradiation; Cisplatin; Docetaxel

Indexed keywords

CISPLATIN; DOCETAXEL; OROSOMUCOID;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG HYPERSENSITIVITY; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; INOPERABLE CANCER; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIATION DOSE FRACTIONATION; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; RADIATION DOSAGE; TAXOIDS; THORAX; TREATMENT OUTCOME;

EID: 33744467951     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0176-3     Document Type: Article

References (27)

1. Dillman RO, Herndon J, Seagren SL et al (1996) Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88:1210-1215
2. Le Chevalier T, Arriagada R, Quiox E et al (1991) Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of randomized trial in 353 patients. J Natl Cancer Inst 83:417-423
3. Sause W, Kolesar P, Taylor S et al (2000) Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer. Chest 117:358-364
4. Schaake-Koning C, van den Bogaert W, Dalesio M et al (1992) Effects of concurrent cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524-530
5. Jeremic B, Shibamoto Y, Acimovic L et al (1996) Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/ etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 14:1065-1070
6. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311:899-909
7. Furuse K, Fukuoka M, Kawahara M et al (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung caner. J Clin Oncol 17:2692-2699
8. Curran WJ Jr, Scott C, Langer C et al (2000) Phase III comparison of sequential vs concurrent chemoradiation for PTS with unresected stage III non-small cell lung cancer (NSCLC): Initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol 19:484a
9. Hei TK, Piao CQ, Geard CR et al (1994) Taxol and ionizing radiation: interaction and mechanisms. Int J Radiat Oncol Biol Pys 29(2):267-271
10. Hennequim C, Giocanti N, Favaudon V (1996) Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res 56(8):1842-1850
11. Choy H, Rodriguez F, Koester S et al (1992) Synergistic effects of toxol/taxotere on radiation sensitivity on human cell lines. Int J Radiat Oncol Biol Phys 24(suppl):274-275
12. Mauer AM, Masters GA, Haraf DJ et al (1998) Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 16:159-164
13. Aamdal S, Wibe E, Hallen MN et al (1997) Phase I study of concomitant docetaxel (Taxotere) and radiation in locally advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 16:460a
14. Koukourakis MI, Kourousis C, Kamilaki M et al (1998) Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial. Eur J Cancer 34:838-844
15. Koukourakis MI, Giatromanolaki A, Schiza S et al (1999) Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation. Int J Radiat Oncol Biol Phys 43:107-113
16. Aamdal S, Hagen I, Avril I et al (1999) Docetaxel (D, Taxotere) with concurrent radiation in locally advanced non-small cell lung cancer. Proc Am Clin Oncol 18:479a
17. Koukourakis MI, Bahlitzanakis N, Froudarakis M et al (1999) Concurrent conventionally fractionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma. Br J Cancer 80:1792-1796
18. Dewitt L (1987) Combined treatment of radiation and cisdiamminedichloroplatinum (II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys 13:403-426
19. Urien S, Barre J, Morin C et al (1996) Docetaxel serum protein binding with high affinity to alpha1-acid gylcoprotein. Invest New Drug 14:147-151
20. Bruno R, Hille D, Riva A et al (1998) Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187-196
21. Robert F, Spencer SA, Childs HA III et al (2002) Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: long-term follow-up of a phase I study. Lung Cancer 37(2):189-199
22. Kiura K, Ueoka H, Segawa Y et al (2003) Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer. Br J Cancer 89:795-802
23. Wu HG, Bang YJ, Choi EK et al (2002) Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in stage III non-small-cell lung cancer. Int J Rad Oncol Biol Phys 52(1):75-80
24. Werner-Wasik M, Pequignot E, Leeper D et al (2000) Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariate analysis of patients with lung cancer treated with nonoperative therapy. Int J Radiat Oncol Biol Phys 48(3):689-696
25. Tsujino K, Hirota S, Endo M et al (2003) Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 55(1):110-115
26. Singh AK, Lockett MA, Bradley JD (2003) Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 55(2):337-341
27. Niho S, Ohe Y, Yokoyama A et al (2003) A phase II study of docetaxel (D) and cisplatin (C) (DC) administered as three consecutive weekly infusions in elderly patients (pts) with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 22:679